Shareholder Votes

Dyne Therapeutics, Inc. shareholders approved Approval of amendment to restated certificate of incorporation to increase authorized common stock from 200,000,000 to 400,000,000 shares at the 2026-06-05 meeting.

“The stockholders of the Company approved an amendment to the Company’s restated certificate of incorporation to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares (the “Authorized Shares Amendment”).”

Dyne Therapeutics, Inc. shareholders approved Non-binding advisory vote on executive compensation at the 2026-06-05 meeting.

“The stockholders of the Company approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.”

Dyne Therapeutics, Inc. shareholders approved Election of Class III directors at the 2026-06-05 meeting.

“The stockholders of the Company elected David Lubner, Brian Posner and Jason Rhodes as Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified.”

Intuitive Machines, Inc. shareholders approved Ratification of Grant Thornton LLP as independent registered public accounting firm at the 2026-06-04 meeting.

“Grant Thornton LLP was ratified as our independent registered public accounting firm for the fiscal year ending December 31, 2026. VOTES FOR VOTES AGAINST VOTES ABSTAINED 246,639,121 280,218 380,473”

Intuitive Machines, Inc. shareholders approved Election of Class III Directors at the 2026-06-04 meeting.

“Class III director nominees were elected for a term expiring in 2029. NOMINEE VOTES FOR VOTES AGAINST BROKER NON-VOTES Dr. Kamal Ghaffarian 195,999,331 22,328,731 28,971,750 Stephen Altemus 207,762,049 10,566,013 28,971,750”

AMERICAN VANGUARD CORP shareholders approved Advisory vote approving the overall executive compensation policies and procedures of the Company at the 2026-06-03 meeting.

“4 - Executive Comp 15,159,605 561,820 338,571 5,335,877”

AMERICAN VANGUARD CORP shareholders approved Advisory vote on the frequency of voting on the overall executive compensation policies and procedures of the Company at the 2026-06-03 meeting.

“3 - Frequency of Comp 14,755,233 10,260 1,040,509 253,994”

AMERICAN VANGUARD CORP shareholders approved Ratification of Deloitte Touche, LLP as independent registered public accounting firm at the 2026-06-03 meeting.

“2 - Ratify Deloitte 20,904,030 24,225 467,618 0”

AMERICAN VANGUARD CORP shareholders approved Election of seven directors at the 2026-06-03 meeting.

“With respect to the first proposal in the proxy, the following seven nominees received more votes “for” than “against” and, as a result, were elected to serve as directors for the ensuing year:”

Root, Inc. shareholders approved Approval of an Amendment to the Company's Amended and Restated Certificate of Incorporation to Allow for the Exculpation of Certain Officers.

“4. Approval of an Amendment to the Company's Amended and Restated Certificate of Incorporation to Allow for the Exculpation of Certain Officers The stockholders approved the Amendment to the Company's Amended and Restated Certificate of Incorporation to Allow for the Exculpation of Certain Officers by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 22,990,364 3,404,961 15,288 3,605,582”

Root, Inc. shareholders approved Approval, on an advisory basis, of named executive officer compensation.

“3. Approval, on an advisory basis, of named executive officer compensation The stockholders approved, on an advisory basis, named executive officer compensation, by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 22,550,967 3,842,883 16,763 3,605,582”

Root, Inc. shareholders approved Ratification of Independent Auditor for 2026 at the 2026-12-31 meeting.

“2. Ratification of Independent Auditor for 2026 The stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent auditor for the year ending December 31, 2026, by the following votes: Votes For Votes Against Abstentions 29,857,571 133,613 25,011”

Root, Inc. shareholders approved Election of Class III Directors.

“1. Election of Class III Directors The stockholders elected each of Lawrence Hilsheimer, Alexander Timm and Douglas Ulman as Class III directors, each to serve terms expiring on the date of the Company's 2029 Annual Meeting of Stockholders and until each such director's successor has been duly elected, or if sooner, until the director's death, resignation or removal, by the following votes: Nominee Votes For Votes Against Abstentions Broker Non-Votes Lawrence Hilsheimer 24,496,159 1,902,619 11,835 3,605,582 Alexander Timm 25,543,235 853,515 13,863 3,605,582 Douglas Ulman 23,809,917 2,588,153 12,543 3,605,582”

FUEL TECH, INC. shareholders approved Advisory vote on executive compensation at the 2026-06-04 meeting.

“Proposal 3: Advisory vote on executive compensation For Against Abstain Broker Non-Votes 11,949,173 637,014 187,055 7,278,620”

FUEL TECH, INC. shareholders approved Ratification of RSM US LLP as independent registered public accounting firm at the 2026-06-04 meeting.

“Proposal 2: Ratification of RSM US LLP as the Company ’ s independent registered public accounting firm For Against Abstain 19,552,321 411,581 38,542”

FUEL TECH, INC. shareholders approved Election of Vincent J. Arnone, Douglas G. Bailey, Sharon L. Jones, and Dennis L. Zeitler to the Board of Directors at the 2026-06-04 meeting.

“Proposal 1: Election of Directors Director For Withheld Broker Non-Votes Vincent J. Arnone 10,736,369 2,002,423 7,278,620 Douglas G. Bailey 9,855,836 2,879,056 7,278,620 Sharon L. Jones 12,340,114 397,103 7,278,620 Dennis L. Zeitler 12,323,119 411,581 7,278,620”

CG Oncology, Inc. shareholders approved Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation at the 2026-06-04 meeting.

“Proposal 4: Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation The Company’s stockholders indicated, on an advisory basis, their preference for the frequency of stockholder advisory votes on the compensation of the Company’s named executive officers. The final voting results are as follows: 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 66,962,791 4,269 537,270 116,996 16,216,685”

CG Oncology, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-04 meeting.

“Proposal 3: Advisory Vote on Executive Compensation The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement. The final voting results are as follows: Shares Voted For Shares Voted Against Abstentions Broker Non-Votes 65,894,959 1,603,011 123,356 16,216,685”

CG Oncology, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-04 meeting.

“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Shares Voted For Shares Voted Against Abstentions 83,711,522 4,103 122,386”

CG Oncology, Inc. shareholders approved Election of Class II Directors at the 2026-06-04 meeting.

“Proposal 1: Election of Directors The Company’s stockholders elected the two persons listed below as Class II directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows: Shares Voted For Shares Voted Withhold Broker Non-Votes Name of Directors Elected Christina Rossi 67,531,501 89,825 16,216,685 Victor Tong, Jr. 62,401,874 5,219,452 16,216,685”

Smart Sand, Inc. shareholders approved Approve the ESPP at the 2026-06-02 meeting.

“The stockholders also approved the ESPP. The voting results for this proposal were 25,324,782 shares for, 86,202 shares against, 92,128 shares abstained and 7,477,825 shares were broker non-votes.”

Smart Sand, Inc. shareholders approved Approve the 2026 Plan at the 2026-06-02 meeting.

“The stockholders also approved the 2026 Plan. The voting results for this proposal were 20,547,767 shares for, 4,849,543 shares against, 105,620 shares abstained and 7,477,825 shares were broker non-votes.”

Smart Sand, Inc. shareholders approved Approve, on an advisory basis, the compensation of the Company’s named executive officers for the year ended December 31, 2025 at the 2026-06-02 meeting.

“The stockholders also approved, on a non-binding and advisory basis, the compensation paid to the Company’s named executive officers during the year ended December 31, 2025. The voting results for this proposal were 24,346,879 shares for, 1,061,089 shares against, 94,962 shares abstained a nd 7,477,825 shares were broker non-votes.”

Smart Sand, Inc. shareholders approved Ratify the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-02 meeting.

“The stockholders also approved the proposal to ratify the selection of Grant Thornton LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The voting results for this proposal were 32,849,141 shares for, 14,720 shares against, and 116,894 shares abstained.”

Smart Sand, Inc. shareholders approved Elect Timothy J. Pawlenty as Class I director at the 2026-06-02 meeting.

“The stockholders elected Sharon Spurlin and Timothy J. Pawlenty to serve as Class I members of the Company’s board of directors for a three-year term. The results of the voting are as follows: Name For Withheld Broker Non-Votes Sharon Spurlin 24,307,260 1,195,670 7,477,825 Timothy J. Pawlenty 19,850,422 5,652,508 7,477,825”

Smart Sand, Inc. shareholders approved Elect Sharon Spurlin as Class I director at the 2026-06-02 meeting.

“The stockholders elected Sharon Spurlin and Timothy J. Pawlenty to serve as Class I members of the Company’s board of directors for a three-year term. The results of the voting are as follows: Name For Withheld Broker Non-Votes Sharon Spurlin 24,307,260 1,195,670 7,477,825 Timothy J. Pawlenty 19,850,422 5,652,508 7,477,825”

Red Rock Resorts, Inc. shareholders approved Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-04 meeting.

“Proposal 3: Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 For Against Abstain 503,766,113 99,490 7,824 Broker Non-Votes: 0”

Red Rock Resorts, Inc. shareholders approved Say-on-pay non-binding advisory vote at the 2026-06-04 meeting.

“Proposal 2: "Say-on-pay" non-binding advisory vote For Against Abstain 491,689,658 8,011,727 31,054 Broker Non-Votes: 4,140,988 The foregoing Proposal 2 was approved on an advisory basis.”

Red Rock Resorts, Inc. shareholders approved Election of Directors at the 2026-06-04 meeting.

“Proposal 1: Election of Directors Nominee For Withheld Frank J. Fertitta III 493,503,377 6,229,062 Lorenzo J. Fertitta 490,785,883 8,946,556 Robert A. Cashell, Jr. 482,161,756 17,570,683 Robert E. Lewis 480,681,195 19,051,244 James E. Nave, D.V.M. 482,867,580 16,864,859 Broker Non-Votes: 4,140,988 for each of Mr. Fertitta III, Mr. L. Fertitta, Mr. Cashell, Mr. Lewis and Dr. Nave.”

SUTRO BIOPHARMA, INC. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement for the Annual Meeting at the 2026-06-05 meeting.

“3. Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement for the Annual Meeting: Shares For Shares Against Shares Abstaining Broker Non-Votes 11,329,946 22,412 6,452 2,540,863”

SUTRO BIOPHARMA, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-05 meeting.

“2. Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: Shares For Shares Against Shares Abstaining 13,893,289 501 5,883”

SUTRO BIOPHARMA, INC. shareholders approved Election of three Class II directors at the 2026-06-05 meeting.

“On June 5, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”), and the following proposals were adopted: 1. Election of three Class II directors”

MetaVia Inc. shareholders approved To authorize one or more adjournments of the Annual Meeting to solicit additional proxies in the event there are insufficient votes to approve Proposals 3 and 4 at the 2026-06-08 meeting.

“The stockholders approved the Adjournment Proposal.”

MetaVia Inc. shareholders approved To approve the First Amendment to the 2022 Equity Incentive Plan to increase the aggregate number of shares of Common Stock that may be issued pursuant to awards by 200,000 shares of Common Stock at the 2026-06-08 meeting.

“The stockholders approved the Equity Plan Proposal.”

MetaVia Inc. shareholders approved To approve an amendment to the Company's Third Amended and Restated Certificate of Incorporation, as amended, to effect a reverse split of the Company's outstanding Common Stock at a ratio in the range of 1-for-5 to 1-for-22 to be determined at the discretion of the Company's Board of Directors at the 2026-06-08 meeting.

“The stockholders approved the Reverse Stock Split Proposal.”

MetaVia Inc. shareholders approved To ratify the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-08 meeting.

“The stockholders ratified the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”

MetaVia Inc. shareholders approved To elect two Class I directors, each to serve a three-year term until the 2029 annual meeting of stockholders and until the election and qualification of such director's successor, or such director's earlier death, resignation, or removal at the 2026-06-08 meeting.

“D. Gordon Strickland and James P. Tursi, M.D. were elected as Class I directors to serve until the 2029 annual meeting of stockholders.”

OPENLANE, Inc. shareholders approved Ratification of Appointment of KPMG LLP at the 2026-06-05 meeting.

“4. Ratification of Appointment of KPMG LLP: FOR AGAINST ABSTAIN 116,244,513 756,707 221,618”

OPENLANE, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-05 meeting.

“3. Advisory Vote on Executive Compensation: FOR AGAINST ABSTAIN BROKER NON VOTES 110,339,036 2,354,947 220,219 4,308,636”

OPENLANE, Inc. shareholders approved Election of Directors (Other Eight Nominees) at the 2026-06-05 meeting.

“2. Election of Directors (Other Eight Nominees): NAME FOR AGAINST ABSTAIN BROKER NON VOTES Randolph Altschuler 112,134,922 572,270 207,010 4,308,636 Carmel Galvin 110,988,467 1,765,650 160,085 4,308,636 J. Mark Howell 111,390,238 1,508,734 15,230 4,308,636 Stefan Jacoby 107,434,149 5,464,824 15,229 4,308,636 Peter Kelly 112,133,881 766,071 14,250 4,308,636 Michael T. Kestner 108,444,879 4,454,039 15,284 4,308,636 Mary Ellen Smith 111,121,765 1,632,497 159,940 4,308,636 Kelly Tuminelli 112,840,015 58,866 15,321 4,308,636”

OPENLANE, Inc. shareholders approved Election of Director (Nominee Designated by the Apax Investor) at the 2026-06-05 meeting.

“1. Election of Director (Nominee Designated by the Apax Investor):* NAME FOR AGAINST ABSTAIN BROKER NON VOTES Roy Mackenzie 16,939,789 0 0 0”

Ambiq Micro, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2026-06-08 meeting.

“The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Ambiq Micro, Inc. shareholders approved Election of Directors at the 2026-06-08 meeting.

“The Company’s stockholders elected the two Class I directors listed below, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified or until their earlier death, resignation or removal.”

IONIS PHARMACEUTICALS INC shareholders approved Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year at the 2026-06-04 meeting.

“Proposal 5: Ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year: FOR AGAINST ABSTAIN BROKER NON-VOTES 148,893,646 4,000,539 150,525 0 The Company’s stockholders approved the foregoing proposal.”

IONIS PHARMACEUTICALS INC shareholders approved Approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance under such plan by 750,000 shares and to remove the termination date of the plan at the 2026-06-04 meeting.

“Proposal 4: Approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance under such plan by 750,000 shares and to remove the termination date of the plan: FOR AGAINST ABSTAIN BROKER NON-VOTES 140,348,001 332,204 58,810 12,305,695 The Company’s stockholders approved the foregoing proposal.”

IONIS PHARMACEUTICALS INC shareholders approved Approval of an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares at the 2026-06-04 meeting.

“Proposal 3 : Approval of an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares: FOR AGAINST ABSTAIN BROKER NON-VOTES 108,377,084 32,303,288 58,643 12,305,695 The Company’s stockholders approved the foregoing proposal.”

IONIS PHARMACEUTICALS INC shareholders approved An advisory vote on the compensation paid to the Company's executive officers at the 2026-06-04 meeting.

“Proposal 2 : An advisory vote on the compensation paid to the Company’s executive officers, including the following resolution: “RESOLVED, that Ionis’ stockholders approve, on an advisory (nonbinding) basis, the compensation of the named executive officers, as disclosed in this Proxy Statement for the 2026 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission.” FOR AGAINST ABSTAIN BROKER NON-VOTES 135,537,973 5,088,105 112,937 12,305,695 The Company’s stockholders approved the foregoing proposal.”

IONIS PHARMACEUTICALS INC shareholders approved Election of directors to hold office until the 2029 Annual Meeting at the 2026-06-04 meeting.

“The Company held its virtual Annual Meeting of Stockholders on June 4, 2026. The stockholders considered five proposals, each of which is described in more detail in the Company’s definitive proxy statement dated April 23, 2026. Proposal 1: Election of directors to hold office until the 2029 Annual Meeting: FOR AGAINST ABSTAIN BROKER NON-VOTES Spencer R. Berthelsen 119,824,353 20,816,547 98,115 12,305,695 Joan E. Herman 135,599,646 5,076,895 62,474 12,305,695 The Company’s stockholders elected the foregoing candidates by affirmative votes by a majority of the votes of the shares represented in person or by proxy at the meeting and entitled to vote in the election of directors.”

Canterbury Park Holding Corp shareholders approved To approve an amendment to the Company’s Stock Plan to increase the number of shares authorized to be issued under the Stock Plan by 200,000. at the 2026-06-04 meeting.

“Proposal 3 — To approve an amendment to the Company’s Stock Plan to increase the number of shares authorized to be issued under the Stock Plan by 200,000. FOR AGAINST ABSTAIN BROKER NON-VOTE 2,640,501 278,550 6,924 1,771,556”

Canterbury Park Holding Corp shareholders approved To ratify and approve the appointment of Wipfli LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-04 meeting.

“Proposal 2 — To ratify and approve the appointment of Wipfli LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. FOR AGAINST ABSTAIN 4,668,915 4,222 24,394”